Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

NCT00023881 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Lack of efficacy

Conditions

Leukemia

Interventions

DRUG: bortezomib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]